图布林聚合抑制剂在早期临床研究中作为癌症治疗药物
Ahmed Kamal1, Rahaman Shaik2, Prasanna Anjaneyulu Yakkalaa2
1Department of Chemistry, Osmania University, Hyderabad, India.
Expert opinion on investigational drugs
|March 4, 2026
概括
图布林聚合抑制剂 (TPI) 在癌症治疗中至关重要. 本综述考察了早期临床TPI,突出了它们的演变成为针对癌症治疗的精密药物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 微管对于癌细胞的分裂和功能至关重要.
- 抑制素聚合是一种关键的抗癌药物开发策略.
- 布林聚合抑制剂 (TPI) 针对这些必要的细胞过程.
研究的目的:
- 在临床早期阶段审查TPI.
- 评估它们的分类,临床前和临床数据.
- 探索TPI发展的挑战和未来方向.
主要方法:
- 从2018年1月到2026年1月的文献搜索.
- 使用的数据库:PubMed,Scopus,Embase,科学网络,临床试验.gov,谷歌学者.
- 关键词: 素聚合抑制剂, 临床试验.
主要成果:
- 根据结合部位对TPI进行分类:素,类,税.
- 临床前研究表明抗增殖活性和与其他治疗方法的协同作用.
- 临床试验通过生物标志物评估疗效,毒性和患者选择.
结论:
- 技术药物正在转向针对癌症特异性分子差异的精密药物.
- 像βIII-tubulin这样的生物标志物有助于个性化治疗.
- 纳米技术和免疫治疗的整合有望提高疗效和降低毒性.
相关概念视频
Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Drugs that Destabilize Microtubules
4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Destabilization of Microtubules
3.8K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.8K
Microtubule Formation
8.0K
Microtubules are dynamic structures that undergo continuous assembly and disassembly. They originate from specialized multi-protein complexes known as microtubule organizing centers or MTOCs. Within the MTOC, the point of origin of the microtubule is known as the minus end, while the end radiating outward is the plus end. Microtubules serve two primary functions — the organization of spindle complexes to separate sister chromatids during mitotic or meiotic cell division and the formation...
8.0K


